Comparison Between Excision And Primary Anastomosis Urethroplasty And Tunica Vaginalis Graft Urethroplasty.

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18-50
SponsorSahiwal medical college sahiwal

About this trial

Urethroplasty is considered as a gold standard in treatment of urethral stricture disease having success rate of more than 93% in terms of recurrence of stricture. The objective of the study is to compare the outcome between excision and primary anastomosis (EPA) urethroplasty, a transecting urethroplasty technique and Tunica Vaginalis Graft (TVG) Urethroplasty, a non-transecting urethroplasty technique, in patients with bulbar urethral stricture upto 2cm in length. It will be a Randomized Controlled Trial (RCT) in which 94 patients admitted in Sahiwal Teaching Hospital, Sahiwal will be included. The patients will be divided into two equal groups. Randomization will be performed using a computer-generated random sequence. The Group-A patients will undergo excision and primary anastomosis (EPA) urethroplasty while Group-B patients will undergo Tunica Vaginalis Graft (TVG) Urethroplasty. Non-probability convenience sampling will be carried out. Detailed history of urinary symptoms, Sexual function, catheterization, instrumentation, urinary tract infection and trauma will be taken to obtain the cause of stricture. Demographic information like name, age, and contact number will be recorded. Investigations will include preoperative complete blood count, renal function test, liver function test, urine complete examination, ultrasonogram kidney, ureter and bladder with post void residual volume (PVR) uroflowmetry and retrograde urethrogram for diagnosis and length of stricture. Other parameters of study will be length of hospital stay, postoperative complication such as graft failure, wound infection, urinary tract infection and fistula formation. Data will be collected through proforma, which will be entered and analyzed using statistical package for social sciences version 26.0. For quantitative variables mean and standard deviation will be calculated and for qualitative variables frequency and percentages will be calculated. Data will be presented in tables and graphs for both quantitative and qualitative variables. Chi-square test will be used to estimate the association between qualitative variables. An Independent sample t-test will be applied for quantitative variables. P-value \<0.05 will be considered significant. It is anticipated that the Tunica Vaginalis Graft (TVG) Urethroplasty provides better outcome as compared to excision and primary anastomosis (EPA) urethroplasty.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with diagnosis of bulbar urethral stricture upto 2cm in length.

Patients aged between 18-50 years.

Patients with non-traumatic bulbar urethral stricture.

Isolated short (≤ 2 cm) bulbar urethral stricture

Disqualifiers

Urethral stricture which is completely obliterated stricture.

Patients with history of hypospadias or previous open urethral surgery.

Patients with uncontrolled diabetes or Immunocompromised patients.

Patients unwilling for the follow-up.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Excision and Primary Anastomosis Urethroplasty

    Procedure/Surgery

    In Excision and Primary anastomosis urethroplasty patients, an incision will be made down onto the urethra at the level of stricture in the ventral midline. Urethra will be divided with scissors proximally and distally until healthy urethra is entered. Stay sutures will be placed. The scarred urethra will be excised, and the healthy proximal urethral segment will be spatulated dorsally so that it accommodates a 30Fr bougie and the distal urethra will then be spatulated ventrally. The anastomosis will be done using interrupted sutures of 4-0 polydioxanone (PDS).

  • Tunica Vaginalis Graft Urethroplasty

    Procedure/Surgery

    In Tunica Vaginalis Graft Urethroplasty patients, an incision will be made onto the urethra in the ventral mid-line along the stricture length, opening into healthy proximal and distal urethra and stay sutures will be positioned. Tunica vaginalis graft is harvested by making a small vertical or transverse hemiscrotal incision. The dartos fascia is divided to expose the tunica vaginalis. The testis is gently delivered through the incision.The tunica vaginalis graft outlined and harvested. The tunica vaginalis defect is approximated and testis is placed back into the scrotum. The dartos and skin are closed in layers using absorbable sutures. The graft will be laid as a ventral onlay graft onto the opened urethral defect and sutured to the urethral mucosal edges using absorbable sutures. Quilting or anchoring sutures may be placed to reduce graft dead space and enhance take. Ventral urethrotomy is closed over the catheter using absorbable sutures.

Treatment groups

94 Participants
are divided into 2 treatment groups
Group A: Excision and Primary Anastomosis UrethroplastyOther 1 intervention
Group B: Tunica Vaginalis Graft UrethroplastyOther 1 intervention

Trial outcomes

Primary outcomes

1

Stricture Recurrence

Defined as the presence of a recurrent stricture on retrograde urethrogram (RUG) or the need for any secondary intervention (e.g., dilatation, direct visual internal urethrotomy, or repeat urethroplasty) within 12 months of the initial surgery.

Time frame
12 months

Secondary outcomes

1

Maximum Urine Flow Rate (Qmax)

The highest rate of urine flow in milliliters per second (mL/s) as measured by uroflowmetry. The primary analysis will compare the mean change in Qmax postoperatively.

Time frame
12 months
2

Erectile Dysfunction

Erectile dysfunction (ED) has been defined as the inability to attain or maintain penile erection sufficient for successful sexual intercourse. The severity of erectile dysfunction is often described as mild, moderate, or severe according to International Index of Erectile Function (IIEF5) questionnaire, with a score of 1-7 indicating severe ED, 08-11 moderate ED, 12-16 mild-moderate ED, 17-21 mild ED, and 22-25 no ED.

Time frame
12 months

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: